PDCD1 and neoplasm: Secondly, for OVs combined with PD-1/PD-L1 blockade, Cervera et al. reported a preclinical study that concomitant delivery of adenoviruses armed with TNF-a and IL-2 and PD-1 blocking antibodies resulted in complete tumor regression in the B16.